LANGUAGE
KOREANENGLISH
LOCATION
  • COMPANY
  • R&D
    • R&D Institute
    • GMP Manufacturing Facility
    • Clinical Development Status
    • Publications
  • PRODUCTS
    • 1st Generation
      • Overview
      • CARTISTEM®
      • PNEUMOSTEM®
    • 2nd Generation
      • Overview
      • SMUP-IA-01
      • SMUP-IV-01
    • R&D Inquiries
  • BUSINESS
    • CDMO
      • Quality System
      • CDMO Service
      • Quality Control
      • Global CDMO
      • CDMO Inquiries
    • CELLTREE Cord Blood Bank
    • MOVITA Nutritional Supplements
  • IR
    • Stock Information
    • Disclosure
    • Financial Information
    • IR Inquiries
  • PR
    • MEDIPOST on Media
    • Corporate Brochure
  • CONTACT US
    • Customer Center
    • R&D Inquiries
    • CDMO Inquiries
    • IR Inquiries
MEDIPOST’s CEO Dr Yang Yoonsun Named on the Forbes 2020 List of Asia’s Power Businesswomen
2020/09/16
MEDIPOST

· In recognition of her achievement in founding and growing MEDIPOST as Korea’s largest private cord blood bank and stem cell therapeutics biotech company

MEDIPOST, a leading stem cell biotechnology company, today announced the company’s founder and chief executive officer Yang Yoonsun MD PhD has been named as one of 25 individuals to the Forbes 2020 list of Asia’s Power Businesswomen.

Included in the list released by Forbes Global are 25 outstanding female entrepreneurs who have played a pivotal role in shaping the business environment across Asia by overcoming difficulties and challenges in various industries such as biotechnology, fintech, and entertainment.

Yang, a widely recognized authority in the field of the cord blood and stem cell technology, received MD PhD from Seoul National University School of Medicine and found MEDIPOST in 2000 while working as a medical doctor at the prominent Samsung Medical Center. Yang was in the list in recognition of her untiring efforts in the growth of MEDIPOST as Korea’s largest private cord-blood bank and the country’s leading stem cell biotech company which has successfully developed CARTISTEM®, the world’s first regulatory-approved stem cell therapy product based on allogeneic umbilical cord blood-derived mesenchymal stem cells.

In terms of countries from which the 25 female entrepreneurs came from, India topped the list with four businesswomen, followed by Thailand and China having three persons each. Korea, Australia, Singapore, Japan, Vietnam and Indonesia had two persons each with Malaysia, the Philippines and Hong Kong having one each.

· Forbes ‘2020 Asia’s Power Businesswomen’ List :
https://www.forbes.com/sites/forbesasiateam/2020/09/14/forbes-asias-power-businesswomen-2020-list/#a8f3e8c74d26

· Image Source : forbes.com – 2020 Asia’s Power Businesswomen

VIEW LIST

Related News

MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022/12/01
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge2022/10/17
Canada’s OmniaBio, MEDIPOST affiliate begins CDMO cGMP for cell gene therapy2022/10/07
MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award2022/07/18

Latest News

MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.
2022/12/01
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge
2022/10/17
Canada’s OmniaBio, MEDIPOST affiliate begins CDMO cGMP for cell gene therapy
2022/10/07
MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award
2022/07/18
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products
2022/05/31

Contacts

21, Daewangpangyo-ro 644, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea MEDIPOST Co., Ltd.
TEL : 82-2-3465-6677

CS CENTER
ONLINE INQUIRY

Latest News

·
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022.12.01
·
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge2022.10.17
·
Canada’s OmniaBio, MEDIPOST affiliate begins CDMO cGMP for cell gene therapy2022.10.07
·
MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award2022.07.18
·
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products2022.05.31

Family Site

· CELLTREE Cord Blood Bank
· MOVITA Nutritional Supplements

· LOCATION
· PRIVACY POLICY

©Copyright – The Future of Biotechnology, MEDIPOST